By expanding aggressively in both China and the United States, the company offers a superior end-to-end solution for ADC contract manufacturing services
Based on its recent analysis of the global antibody drug conjugate (ADC) contract manufacturing services market, Frost & Sullivan recognizes China-based MabPlex International, Ltd (MabPlex) with the 2019 Global Growth Excellence Leadership Award. MabPlex emerges as one of the few large-scale, end-to-end ADC producers, providing services from early-stage development to commercialization. The company’s proprietary conjugation platform and innovative technologies deliver novel and clinically effective ADCs for cancer therapeutics around the world.
“While rapidly expanding its operations in China, MabPlex also established a center of excellence in the United States. Its first manufacturing facility (M1) in Shandong provides an integrated solution supporting early-stage clinical manufacturing of antibodies, recombinant proteins, and ADCs. MabPlex’s second Shandong-based facility (M2) opened in 2018 as it anticipated the advancement of ADCs in later-stage development encouraged by the rising global bio-manufacturing capacity demand,” said Khushbu Jain, Industry Analyst at Frost & Sullivan. “M2 has built upon the current process development facility by adding six new cell culture (upstream) suites, and all single-use stirred-tank bioreactors.”
Meanwhile, the company’s San Diego facility in the United States (US) has a team that engages early with clients and communicates with pharmaceutical partners in Europe, the US, and the rest of the Western market. MabPlex’s services cover the entire spectrum—from gene sequencing to cell line development, process characterization, conjugation optimization to Current Good Manufacturing Practice (cGMP) clinical and commercial manufacturing of final drug product for biopharmaceutical companies. The San Diego facility currently has a scale-up capacity of up to 200 liters and provides an exceptional integrated solution supporting cell-line development, upstream and downstream process development, ADC, analytical testing, and formulation development.
MabPlex’s solution minimizes external touchpoints and facilitates timely interfacility communication. A unified supply chain ensures efficiencies across the board, allowing MabPlex to save scheduling and testing time, eliminate rescheduling due to supply chain delays, limit inventory and logistical management concerns, and reduce product transfer related risks. These enhanced efficiencies lower the company’s overhead costs, which gives it one of the most competitive pricing models in the industry.
“MabPlex’s technology enables consistent drug-to-antibody-ratio for each manufacturing lot,” noted Jain. “In the US, its focus is on ADC pipeline growth, client engagement, and co-development partnerships specializing in ADC development. Overall, its ability to deliver quality manufacturing services while lowering time to market makes it the partner of choice for ADC development.”
Each year, Frost & Sullivan bestows this award upon the company that demonstrates excellence in growth and customer value. It recognizes the superiority of the product/service as well as the overall customer, purchase, ownership, and service experience offered, which has resulted in the recipient company seeing above-market growth and greater share of wallet. The award lauds the growth, diversification, and sustainability strategies of the company.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About MabPlex International
MabPlex, a leading and fully integrated Contract Development and Manufacturing Organization (CDMO), offers an advanced biologics platform with a comprehensive, integrated solution for global biopharmaceutical developers. Founded in 2013, MabPlex currently has two sites in China (Yantai and Shanghai) and one site in the United States (San Diego, CA) offering high quality services from biologics drug development to commercial manufacturing for antibodies, recombinant proteins, and antibody drug conjugates (ADCs). With our state-of-the-art facilities and exemplary biologics development and manufacturing experience, MabPlex commits to being a valuable partner for our clients around the globe.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Contact:
Lindsey Whitaker
P: +1 (210) 477-8457
E: lindsey.whitaker@frost.com
